#1 Clinical Trials Search in Europe

Study of Teclistamab with Daratumumab or Lenalidomide for Elderly Patients with Newly Diagnosed Multiple Myeloma

2 1 1 1

What is this study about?

This clinical trial is focused on studying a disease called Multiple Myeloma, which is a type of cancer that affects the bone marrow. The study is testing a new treatment approach using a combination of medications. The medications being studied are Teclistamab, Daratumumab, and Lenalidomide. Teclistamab is a special type of protein called a bispecific antibody, which is designed to help the immune system target and destroy cancer cells. Daratumumab is another antibody that works by attaching to cancer cells and helping the immune system to eliminate them. Lenalidomide is a medication that helps to slow down or stop the growth of cancer cells.

The purpose of this study is to evaluate how effective the combination of these medications is in treating elderly patients who have been newly diagnosed with Multiple Myeloma. Participants in the study will receive these medications through injections or capsules over a period of time. The study will monitor the participants’ responses to the treatment, looking for improvements in their condition. The study will also keep track of any side effects that may occur during the treatment.

Throughout the study, participants will undergo regular check-ups to assess their health and the progress of the treatment. The study aims to determine if the combination of these medications can provide a significant benefit to patients with Multiple Myeloma, potentially leading to better treatment options in the future. The study is expected to continue for several years to gather comprehensive data on the effectiveness and safety of the treatment.

1 initial assessment

Upon joining the study, an initial assessment is conducted to confirm eligibility. This includes reviewing medical history and current health status.

Eligibility criteria include being at least 65 years old and having a documented diagnosis of multiple myeloma.

2 treatment initiation

The treatment phase begins with the administration of teclistamab and either daratumumab or lenalidomide.

Teclistamab and daratumumab are given as subcutaneous injections, while lenalidomide is taken orally.

3 treatment cycles

The treatment is organized into cycles. Each cycle involves regular administration of the medications as prescribed by the study protocol.

The primary goal is to achieve a very good partial response or better after four cycles of treatment.

4 monitoring and evaluation

Throughout the study, regular monitoring is conducted to evaluate the response to treatment and any side effects.

Assessments include measuring the rate of response and monitoring for any adverse events.

5 completion of treatment

The study aims to continue treatment until the desired outcomes are achieved or until the study’s end date.

The estimated end date for the study is December 21, 2030.

Who Can Join the Study?

  • The patient must be at least 65 years old.
  • The patient must have a confirmed diagnosis of multiple myeloma, which is a type of cancer affecting plasma cells in the bone marrow. This includes having certain levels of plasma cells or specific signs of the disease, such as high calcium levels, kidney problems, anemia, or bone damage.
  • The patient must have an ECOG performance status score of 0, 1, or 2, which is a scale used to assess how well a patient can perform daily activities.
  • The patient should not be considered for high-dose chemotherapy with ASCT (autologous stem cell transplant).
  • The patient must have certain laboratory test results, such as:
    • Hemoglobin levels of at least 8 g/dL without recent blood transfusions.
    • Platelet count of at least 75,000 per microliter if less than 50% of bone marrow cells are plasma cells, or at least 50,000 per microliter if 50% or more are plasma cells.
    • Absolute neutrophil count of at least 1,000 per microliter.
    • AST and ALT levels no more than 2.5 times the upper limit of normal.
    • eGFR (a measure of kidney function) of at least 30 mL/min.
    • Total bilirubin levels no more than 2 times the upper limit of normal, unless the patient has a condition like Gilbert’s syndrome.
    • Serum calcium levels within a certain range.
  • A male patient must use a condom during activities that could result in pregnancy during the study and for a specified time after the last dose of study medication. If the female partner can become pregnant, she must also use a highly effective birth control method.
  • A male patient must agree not to donate sperm for a specified time after the last dose of study medication.
  • The patient must sign an informed consent form, indicating they understand the study’s purpose and procedures and agree to participate.
  • The patient must be willing and able to follow the study’s rules and restrictions as outlined in the informed consent form.

Who Cannot Join the Study?

  • Patients with other serious health conditions that could interfere with the study.
  • Patients who are pregnant or breastfeeding.
  • Patients who have had another type of cancer in the past, unless it was treated and has not come back for a certain period.
  • Patients who have had a recent infection that required treatment with antibiotics.
  • Patients who have received certain treatments for their condition within a specific time before the study starts.
  • Patients who have allergies to the study medications or their ingredients.
  • Patients who have participated in another clinical trial recently.
  • Patients who have a history of drug or alcohol abuse.
  • Patients who have certain heart conditions or have had a heart attack recently.
  • Patients who have uncontrolled high blood pressure.
  • Patients who have certain liver or kidney problems.
  • Patients who have a history of certain lung diseases.
  • Patients who have a history of certain blood disorders.
  • Patients who have a history of certain immune system disorders.
  • Patients who are unable to follow the study procedures or instructions.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
Oncopole Claudius Regaud Toulouse France
Centre Hospitalier Universitaire De Bordeaux Bordeaux France
Centre Hospitalier Universitaire De Lille Lille France
CHU Grenoble Alpes La Tronche France

Other Sites

Site Name City Country Status
Centre Hospitalier De Versailles Le Chesnay-Rocquencourt France
Centre Hospitalier Universitaire De Poitiers Poitiers France
Centre Hospitalier D Avignon Avignon France
Centre Hospitalier Universitaire De Montpellier Montpellier France
Centre Hospitalier De La Cote Basque Bayonne France
Centre Hospitalier Universitaire De Nantes Nantes France
Centre Hospitalier Universitaire Amiens Picardie Amiens France
Groupe Hospitalier De La Region De Mulhouse Et Sud Alsace Mulhouse France
Centre Hospitalier Universitaire De Rennes Rennes France
Centre Hospitalier Lyon Sud Pierre Benite France
Hopital Beaujon Clichy France
Centre Hospitalier Universitaire De Caen Normandie Caen France
L’Hopital Alexandra Lepeve Dunkirk France
Centre Hospital Region Metz Thionville Metz France
Cbmltm Lkrb Bnhiru Lyon France
Cmjsxv Hrsqdqxqcqe Udiabsxjwxbxj Rmyne Reims France
Aug Lzlglqdm Tbktdjzfbb Ifssldes Rdgplm Vandoeuvre Les Nancy France
Coyhzj Hyzywilocqk Ev Udjnxmodcrssn Dc Lpsnrrx Limoges France
Cddsmh Hhmjmctxgwl Umvjobcxhmjyw Dn Dsucj Dijon France
Bwnbnvnt Ucxvppboyh Hxlctwtx Cyfbzs Besançon France
Cvhxrv Hzlmhvqwunz Rpymcrus Uvguazvnxllip Dk Tewnz Tours France
Cphxxn Hyhlenjekpp Rovmtfqv Diwkxcizdohbhi Angers France
Hulhbwbv Uqurnwkqhdubej Spmocqmruv &jwizxv Hwliwzx du Hsxefbpadxx STRASBOURG, Alsace France

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
France France
Recruiting
21.12.2023

Trial locations

Investigated drugs:

Teclistamab is an investigational medication being studied for its potential to treat multiple myeloma, a type of blood cancer. It is designed to help the immune system target and destroy cancer cells more effectively.

Daratumumab is a medication used to treat multiple myeloma. It works by attaching to a specific protein on the surface of cancer cells, helping the immune system to identify and eliminate these cells.

Lenalidomide is a medication used in the treatment of multiple myeloma. It helps the immune system fight cancer by enhancing the body’s natural defense mechanisms and directly attacking cancer cells.

Investigated diseases:

Multiple Myeloma – Multiple Myeloma is a type of blood cancer that affects plasma cells, which are a kind of white blood cell found in the bone marrow. In this disease, cancerous plasma cells multiply and crowd out healthy blood cells, leading to issues such as anemia, bone damage, and kidney problems. As the disease progresses, it can cause bone pain, frequent infections, and fatigue due to the overproduction of abnormal proteins. These proteins can also lead to kidney damage and other complications. The disease often progresses slowly, but it can become more aggressive over time. It is considered a rare disease and requires careful monitoring to manage its symptoms and progression.

Trial ID:
2024-514101-65-00
Protocol code:
2022_0174
NCT ID:
NCT05572229
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • A study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant

    Recruiting

    4 1 1 1
    Investigated diseases:
    Investigated drugs:
    France Norway Spain

  • A study testing etentamig alone or with drug combinations in adult patients with multiple myeloma to assess safety and changes in disease activity

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Norway